GlassScriptPhysician profile
Benjamin N Massat
NPI 1659909711
$614.38
in general payments reported to CMS, 2019-2025
9 companies · $276 in 2025
The $276 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $154 · 2024: $185 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $194.39 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $125.16 | 2023 | Reblozyl |
| Gamida Cell INC. | $106.33 | 2025 | Omisirge |
| Incyte Corporation | $57.18 | 2023-2024 | Jakafi |
| Beigene USA, INC. | $35.00 | 2025 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $32.51 | 2024 | |
| Adaptive Biotechnologies Corporation | $22.51 | 2025 | Clonoseq |
| Sobi, INC | $21.39 | 2025 | |
| Janssen Pharmaceuticals, INC | $19.91 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Massat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.